Monitor for topline Phase 3 CATT1 data in 2H 2026, which will be a critical catalyst for the stock. The current cash position provides sufficient runway to reach this milestone.
VTVT drugs
VTVT drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Feb 26 $39.32entry
- T+1 · 9mo ago −2.95%α −2.50% · $38.16
- T+5 · 9mo ago −5.34%α −4.21% · $37.22
- T+20 · 8mo ago −3.87%α +2.54% · $37.80
- T+60 · 6mo ago −9.72%α −17.47% · $35.50
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
vTv Therapeutics released an investor presentation disclosing that its lead asset, Cadisegliatin, is in Phase 3 development for type 1 diabetes, with topline data expected in the second half of 2026. The company highlighted a strong balance sheet with $118.5 million in cash, providing runway past the data readout. No new financial guidance or clinical results were provided.
Key Facts
- Cadisegliatin is in Phase 3 development for type 1 diabetes with topline CATT1 data targeted for 2H 2026
- Company has $98.5M cash as of 9/30/2025 plus $20.0M received on 2/2/2026, totaling $118.5M
- Cadisegliatin has FDA Breakthrough Therapy Designation for treatment of T1D
- Presentation contains forward-looking statements about future operations and financial performance
Financial Impact
$118.5 million cash runway through 2H 2026
Risk Factors
- Clinical trial failure risk for Cadisegliatin
- Dependence on successful Phase 3 results for company valuation
- Dilution risk if additional funding is needed beyond current runway
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001641489-26-000005 |
| Document: vtvt-20260226.htm | 0001641489-26-000005 |
| Document: 0001641489-26-000005-index-headers.html | 0001641489-26-000005 |
| Document: 0001641489-26-000005-index.html | 0001641489-26-000005 |
| Document: 0001641489-26-000005.txt | 0001641489-26-000005 |
Track record
9 reports on VTVT
Filters
- Nov 16, 2026today SC 13D/A Neutral 3/10 Entry $17.69 Now $17.69 +0.00% settles Dec 16
- Nov 12, 20264d ago 144 Neutral 3/10 Entry $19.69 Now $17.69 −10.16% settles Dec 14
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Neutral 4/10 Entry $21.03 Now $17.69 −15.88% settles Dec 7
- Oct 8, 20265w ago SC 13G/A Neutral 3/10 Entry $31.18 to $21.03 Now $17.69 −43.26% ▼ −32.55% −26.99% vs SPY
- Jun 10, 202622w ago DEFA14A Neutral 3/10 Entry $31.59 to $33.44 Now $17.69 −44.00% ▲ +5.86% +3.97% vs SPY
- May 8, 202627w ago Press Release Neutral 2/10 Entry $30.46 to $31.77 Now $17.69 −41.92% ▲ +4.30% +4.61% vs SPY
- Mar 10, 202635w ago Press Release Mixed 6/10 Entry $35.10 to $37.30 Now $17.69 −49.60% ▲ +6.27% +5.74% vs SPY
- Feb 26, 202637w ago 8-K Neutral 4/10 Viewing Entry $39.32 to $37.80 Now $17.69 −55.01% ▼ −3.87% +2.54% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers